WEHI-539, CAS 1431866-33-9

Product Description: WEHI-539 is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM.

Applications: Cancer-programmed cell death

Formula: C31H29N5O3S2

Citations: Am J Cancer Res. 2019 Dec 1;9(12):2580-2598./Breast Cancer Res Treat. 2019 Feb;173(3):585-596./Cancer Biology. 2020 May./Cell Death Differ. 2014 Jul;21(7):1170-7. /Cell Death Differ. 2017 Jan;24(1):111-119. /Cell Death Dis. 2017 Dec 13;8(12):3216./Cell Death Dis. 2023 Oct 28;14(10):705./Cell. 2014 Dec 18;159(7):1549-62./Clin Cancer Res. 2019 Dec 1;25(23):7139-7150. /J Ovarian Res. 2016 Apr 14;9(1):25. /Nat Commun. 2016 Mar 9;7:10916./Nature. 2017 Nov 9;551(7679):247-250. /Oncol Rep. 2019 Dec;42(6):2416-2425./Pharmacol Res. 2022 Dec 21;187:106628./Acta Pharmacol Sin. 2024 Aug 26./bioRxiv. 2023 Aug 5./Blood. 2014 Dec 4;124(24):3587-96. /Cell Death Dis. 2018 Jan 19;9(2):42./Cell Rep. 2023 Mar 30;42(4):112324./Cell. 2014 Dec 18;159(7):1549-62./Immunity. 2024 Jun 11;57(6):1289-1305.e9./Int J Cancer. 2018 Feb 1;142(3):584-596./Malays Appl Biol. (2020) 49(1): 193-197./Methods Mol Biol. 2018;1711:351-398./Nat Biotechnol. 2018 Feb;36(2):179-189./Nat Cancer. 2024 May 30./Nat Chem Biol. 2022 Jun;18(6):615-624./Nature. 2017 Nov 9;551(7679):247-250. /Oncotarget. 2018 May 25;9(40):26046-26063./The Department of Medical Sciences, Harvard University. 2019 Dec.

References: [1]Lessene G, et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol. 2013 Jun;9(6):390-7./[2]Abed MN, et al. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 2016 Apr 14;9:25.

CAS Number: 1431866-33-9

Molecular Weight: 583.72

Compound Purity: 95.05

Research Area: Cancer

Solubility: 10 mM in DMSO

Target: Bcl-2 Family

• Artikelnummer: MEXHY-15607-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-15607-1
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK